https://www.selleckchem.com/pr....oducts/avitinib-ac00
Using the tumor growth rate, 90% of all patients showed a tumor reduction between first and final response evaluation. The 6-month, 1-, 2- and 3-year overall survival rates were 86.5%, 67.4%, 47.2%, and 33.7%, with a median survival of 45, 24, 15, and 14 months for complete response, partial response, stable disease, and progressive disease, respectively. Tumor reduction showed a positive effect on survival. DEB-TACE offers conclusive response results with mRECIST and proves a strong tendency of tumor reduction on survival benef
Me gusta
Comentario
Compartir
